Teva, biotech firm partner to make cancer drugs work
Israel's Optimata Ltd said on
Tuesday it had signed an agreement with Teva Pharmaceutical
Industries (TEVA.O) (TEVA.TA) to develop drug candidates for
solid tumour cancers.
Optimata's bio-simulation technology allows Teva, the
world's largest generic drug maker, to "fix" drugs that failed
advanced clinical development tests by monitoring changes in
dosing and timing.
Teva will pay for the rights to drugs that have been shelved
by companies after they failed to pass advanced clinical tests,
Optimata said. It added that Teva had also made an undisclosed
investment in Optimata.
Rescuing candidate cancer drugs offers Teva a shortcut to
the cancer drug market, where it hopes to expand.
Optimata's Virtual Patient technology monitors the
interaction of drugs in patients and enables drug developers to
perform clinical trials and to forecast optimal treatments.
•
del.icio.us
digg
facebook
E-mail this article to a friend (requires login).